Stay updated with breaking news from Program Registries. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240...
Despite recent reimbursement struggles, the company said it was raising its full year guidance above its previously estimated $170 million to $180 million.
Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx®-Melanoma and DecisionDx®-UM will be shared... | June 3, 2023